P57: Beckwith-Wiedemann Syndrome
Download
Report
Transcript P57: Beckwith-Wiedemann Syndrome
p57: Beckwith-Wiedemann
Syndrome
Presented By:
Jameeka Carrington
Symptoms of BWS
Large body size (macrosomia)
Large tongue (macroglossia)
Large organs (visceromegaly)
Abdominal wall defects (i.e. umbilical hernia )
Hypoglycemia (low blood sugar)
Symptoms of BWS
Large prominent eyes
Creases in ear lobes
Undescended testicles
Seizures
Symptoms of BWS
Metopic Ridge- a ridge of
bone or suture line on the
forehead between the two
halves of the frontal bone.
The ridging is caused
when the two halves close
prematurely.
www.nlm.nih.gov/medlineplus/ency/article/001186.htm
Symptoms of BWS
Microcephaly- abnormal
smallness of the head
Macroglossia- enlarged
tongue
Umbilical herniaprotrusion of the
intestines through the
abdominal wall in the
navel region
www.nlm.nih.gov/medlineplus/ency/article/001186.htm
Symptoms of BWS
Increased predisposition to tumor development
Wilms’ tumor
Adrenocortical carcinoma
Rhabdomyosarcoma
Hepatoblastoma
Tests for BWS
Bone X-ray
Blood tests for low sugar
Ultrasound of the abdomen
X-ray of the abdomen
MRI of the abdomen
Chromosome studies
Genetic Basis of BWS
85% of cases are sporadic
Inherited in autosomal dominant fashion
Mapped to chromosome 11p15
Translocation breakpoints found within chromosome
map to three distinct regions
Region 1, BWSCR1, contains 5 translocation
breakpoints, which all disrupt the KCNQ1 gene and is
the region of primary concern
Chromosome 11
Steenman et al. (2000) Genes, Chromosomes & Cancer 28:2.
p57
Member of the Cip/Kip family
of mammalian CKI’s along
with p21 and p27
Differs from p21 and p27 in
structure by insert of
proline/alanine rich or acidic
motifs following the Cdk
inhibitory domain
Inhibits G1 cyclin-Cdk
complexes by binding to cyclin
and blocking the catalytic site
of the associated Cdk
Expressed during embryonic
development
The p21 Family of CDK inhibitors
(p21CIP1/WAF1, p27KIP1, p57KIP2)
active
CDK
Cyclin
inactive
+
p21
CDK
p21
Cyclin
p27Kip1
Cyclin A
CDK2
Jeffrey et al. (1995) Nature 376:313
CDK2
Cyclin A
Russo et al. (1996) Nature 382:325
IGFII
Insulin-like growth factor II, or IGFII, is a single chain
polypeptide that is 47% homologous with insulin
Functions
Mediates growth hormone action
Stimulates the growth of cultured cells
Stimulates the action of insulin
Involved in development and growth
Autocrine regulator of cell proliferation
Imprinting of p57 and IGFII
p57 is paternally imprinted in the genome
IGFII is maternally imprinted in the genome
Genomic imprinting is the reversible modification of DNA
that causes differential expression of maternally or paternally
inherited genes
A gene which is imprinted, is inactivated, by being methylated
Imprinting suppresses gene transcription and takes place
during gametogenesis
Chromosome 11 is one of only nine chromosomes that are
suspected to have imprinted regions
p57 and IGFII Act as Antagonists
Several studies have also
shown that IGFII expression
down regulates the activity of
p57
p57 is a negative regulator of
cell proliferation
IGFII is a positive regulator
of cell proliferation
Both over expression of IGFII
and inhibited expression of
p57 result in BWS symptoms
Together, p57 and IGFII act
antagonistically
Grandjean et al. (2000) PNAS 97:5281.
Loss of Imprinting (LOI) and BWS
Imprinting defects of IGFII is
the most prominent cause of the
development of BWS
LOI of IGFII results in
biallelic expression of IGFII,
which down regulates
expression of p57 at an
increased level
Paternal duplication of IGFII
and the presence of a defective
maternal p57 allele contributes
to the development of BWS as
well
Weksburg et al. (2001) Human Molecular Genetics 10:2989-3000.
p57 and BWS
Two separate studies were
conducted using mutant
mice carrying deletions of
the beginning of the p57
gene
Resultant defects common
between both studies
correlate with symptoms
of BWS
Phenotype
BWS
p57KIP2 mutants
IGFII
transgenics
Macroglossia
+
_
nd
Gigantism
+
_
+*
Abdominal defect
+
+
nd
Hypoglycemia
+
_
+
Visceromegaly
+
+
+
Renal dysplasia
+/-
+
nd
Adrenal
cytomegaly
+
+
nd
Intestinal
malrotation
+/-
+
nd
Cleft palate
+/-
+
nd
Neoplasia
+/-
_
+*
Skeletal anomalies
+/-
+
nd
Lens defect
+/-
+
nd
Key: +, observed commonly; +/-, less commonly observed; -, not observed; nd, not
determined; *, observed only in some reports
Swanger, W. Jherek, Roberts, James M. (1997) BioEssays 19:840.
Summary
BWS is an autosomal dominant disorder
characterized by overgrowth and predisposition
to tumor development
p57 and IGFII, both located on chromosome
11, are believed to be highly associated with the
development of BWS
Defects in the imprinting of p57 and IGFII
have been experimentally shown to reproduce
BWS symptoms in mutant mice